Skip to content

Johannes G. Ramaekers

Maastricht University

114 papers in the library · 4,340 citations · publishing 2003-2026

Papers

Sort Most recent Most cited

A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers

Journal of Psychopharmacology August 25, 2020 Johannes G. Ramaekers, Nadia R. P. W. Hutten, Natasha L. Mason et al. 95 citations

Background: Lysergic acid diethylamide (LSD) is an ergot alkaloid derivative with psychedelic properties that has been implicated in the management of persistent pain. Clinical studies in the 1960s and 1970s have demonstrated profound analgesic effects of full doses of LSD in terminally ill patients, but this line of research evaporated after LSD was scheduled worldwide. Aim: The present...

A comparison of reactivation experiences following vaporization and intramuscular injection (IM) of synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting

Journal of Psychedelic Studies March 25, 2020 Malin V. Uthaug, Rafael Lancelotta, Ana María Ortiz Bernal et al. 25 citations

Abstract Background Previous research suggests a therapeutic potential of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). However, online anecdotal reports have described a phenomenon following cessation of the acute effects of 5-MeO-DMT use which has been termed reactivation (i.e., re-experiencing [“flashback”]). To date, no research has investigated whether different routes of administration...

DOI: 10.1556/2054.2020.00123 (opens in new tab) Vaporization Hallucinogen Anesthesia

Acute Effects of 2C-E in Humans: An Observational Study

Frontiers in Pharmacology March 18, 2020 Esther Papaseit, Marta Torrens, Mireia Ventura et al. 20 citations

2,5-Dimethoxy-4-ethylphenethylamine (2C-E) is psychedelic phenylethylamine, with a chemical structure similar to mescaline, used as new psychoactive substance (NPS). It inhibits norepinephrine and serotonin uptake and, more relevant, acts as a partial agonist of the serotonin 2A (5-HT2 A), 2B (5-HT2 B), and (5-HT2 C) receptors. Consumers have reported that 2C-E induces mild-moderate psychedelic...

Cannabis increases susceptibility to false memory

Proceedings of the National Academy of Sciences February 10, 2020 Lilian Kloft, Henry Otgaar, Arjan Blokland et al. 49 citations

With the growing global acceptance of cannabis and its widespread use by eyewitnesses and suspects in legal cases, understanding the popular drug's ramifications for memory is a pressing need. In a double-blind, randomized, placebo-controlled trial, we examined the acute and delayed effects of Δ9-tetrahydrocannabinol (THC) intoxication on susceptibility to false memory in 64 healthy volunteers....

Reduced responsiveness of the reward system is associated with tolerance to cannabis impairment in chronic users

Addiction Biology December 22, 2019 Natasha L. Mason, Eef L. Theunissen, Nadia R. P. W. Hutten et al. 58 citations

Cannabis is the most commonly used illicit drug in the world. However, because of a changing legal landscape and rising interest in therapeutic utility, there is an increasing trend in (long-term) use and possibly cannabis impairment. Importantly, a growing body of evidence suggests that regular cannabis users develop tolerance to the impairing, as well as the rewarding, effects of the drug....

DOI: 10.1111/adb.12870 (opens in new tab) Cannabidiol Context archaeology Dronabinol Effects of cannabis +4

Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment

Psychopharmacology December 10, 2019 Malin V. Uthaug, Rafael Lancelotta, Attila Szabo et al. 116 citations

Abstract Rationale 5-methoxy-N,N-dimethyltryptamine is a psychotropic substance found in various plant and animal species and is synthetically produced. 5-methoxy-N,N-dimethyltryptamine is used in naturalistic settings for spiritual exploration, recreation, or to address negative affect and mood problems. However, scientific knowledge on the effects of 5- methoxy-N,N-dimethyltryptamine in...

Cannabis induced increase in striatal glutamate associated with loss of functional corticostriatal connectivity.

European Neuropsychopharmacology December 1, 2019 Natasha L. Mason, Eef L. Theunissen, Nadia R. P. W. Hutten et al.

Cannabis is the most commonly used illicit drug and is known to alter state of consciousness and impair neurocognitive function. However, the mechanisms underlying these effects have yet to be fully elucidated. Rodent studies suggest that Δ9-tetrahydrocannabinol (THC) activates dopaminergic neurons in the limbic system, subsequently enhancing dopamine, which is implicated in the rewarding...

Reduced responsiveness of the reward system underlies tolerance to cannabis impairment in chronic users

bioRxiv (Cold Spring Harbor Laboratory) July 19, 2019 Natasha L. Mason, Eef L. Theunissen, Nadia R. P. W. Hutten et al. 4 citations preprint

Abstract Cannabis is the most commonly used illicit drug in the world. However due to a changing legal landscape, and rising interest in therapeutic utility, there is an increasing trend in (long-term) use and possibly, cannabis impairment. Importantly, a growing body of evidence suggests regular cannabis users develop tolerance to the impairing, as well as the rewarding, effects of the drug....

False memory formation in cannabis users: a field study

Psychopharmacology June 27, 2019 Lilian Kloft, Henry Otgaar, Arjan Blokland et al. 19 citations

RATIONALE: Cannabis use is widespread and has previously been associated with memory impairments. However, the role of cannabis in relation to false memory production, i.e., memories of events that were not experienced, is less well-understood. OBJECTIVE: The aim of the current field study was to examine the impact of cannabis use on false memory production. METHODS: The...

Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition

Psychopharmacology May 1, 2019 Thomas R. Arkell, Nicholas Lintzeris, Richard C. Kevin et al. 177 citations

BACKGROUND: The main psychoactive component of cannabis, delta-9-tetrahydrocannabinol (THC), can impair driving performance. Cannabidiol (CBD), a non-intoxicating cannabis component, is thought to mitigate certain adverse effects of THC. It is possible then that cannabis containing equivalent CBD and THC will differentially affect driving and cognition relative to THC-dominant cannabis. AIMS:...

Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis.

Psychopharmacology April 9, 2019 Vincent T Mensen, Annabel Vreeker, Johan Nordgren et al.

Background: Synthetic cannabinoids (SCs) are a class of new psychoactive substances that have been rapidly evolving around the world throughout recent years. Many different synthetic cannabinoid analogues are on the consumer market and sold under misleading names, like "spice" or "incense." A limited number of studies have reported serious health effects associated with SC use. In this study,...

DOI: 10.1007/s00213-019-05238-8 (opens in new tab) Full text (opens in new tab) Humans Marijuana abuse Cannabinoids Marijuana smoking +16

Neurocognition and Subjective Experience Following Acute Doses of the Synthetic Cannabinoid JWH-018: Responders Versus Nonresponders

Cannabis and Cannabinoid Research February 27, 2019 Eef L. Theunissen, Nadia R. P. W. Hutten, Natasha L. Mason et al. 22 citations

Abstract Introduction: Synthetic cannabinoid mixtures have been easily accessible for years, leading to the belief that these products were natural and harmless, which contributed to their popularity. Nevertheless, there are many reports of users ending up in hospital due to severe side effects such as tachycardia, aggression, and psychosis. Controlled studies on the effects of synthetic...

DOI: 10.1089/can.2018.0047 (opens in new tab) Cannabis Placebo Neurocognitive Amnesia +4

A First-in-Man Study with 4-Fluoroamphetamine Demonstrates it Produces a Mild Psychedelic State

Journal of Psychoactive Drugs January 24, 2019 Kim P. C. Kuypers, E. B. de Sousa Fernandes Perna, Eef L. Theunissen et al. 13 citations

The phenethylamine 4-fluoroamphetamine (4-FA) is a so-called novel psychoactive substance with a chemical structure resembling that of amphetamine and MDMA. Since 4-FA users report their subjective experience ranges between the effects induced by amphetamine and MDMA, and it is known that both substances can produce an altered state of consciousness, this study tests whether 4-FA induces a...

Independent elevation of peripheral oxytocin concentrations and reduction in cognitive empathy during 4‐fluoroamphetamine intoxication

Human Psychopharmacology: Clinical and Experimental October 25, 2018 Patrick C. Dolder, Elizabeth B. de Sousa Fernandes Perna, Natasha L. Mason et al. 6 citations

OBJECTIVES: 4-Fluoroamphetamine (4-FA) is a novel psychoactive substance with a pharmacological profile and reported subjective effects (e.g., empathy) intermediate between 3,4-methylenedioxymethamphetamine (MDMA) and amphetamine. Studies have shown that MDMA and amphetamine increase emotional empathy without affecting cognitive empathy; MDMA simultaneously leads to elevated levels of oxytocin,...

DOI: 10.1002/hup.2680 (opens in new tab) MDMA Empathy Oxytocin Placebo +4

Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution

Psychopharmacology August 13, 2018 Malin V. Uthaug, Kim van Oorsouw, Kim P. C. Kuypers et al. 213 citations

RATIONALE: Ayahuasca is a psychotropic plant tea from South America used for religious purposes by indigenous people of the Amazon. Increasing evidence indicates that ayahuasca may have therapeutic potential in the treatment of mental health disorders and can enhance mindfulness-related capacities. Most research so far has focused on acute and sub-acute effects of ayahuasca on mental...

Safety Profile and Neurocognitive Function Following Acute 4-Fluoroamphetamine (4-FA) Administration in Humans

Frontiers in Pharmacology July 6, 2018 Elizabeth B. de Sousa Fernandes Perna, Eef L. Theunissen, Patrick C. Dolder et al. 18 citations

Availability of novel psychoactive substances (NPS) exponentially increased over the last years. Risk evaluations of NPS are hampered by the lack of pharmacological studies in humans on health parameters. The aim of the present study was Tto evaluate safety and neurocognitive function of healthy volunteers (N=12) who received single doses of 100 and 150 mg 4-fluoroamphetamine (4-FA), a...

DOI: 10.3389/fphar.2018.00713 (opens in new tab) Neurocognitive Administration probate law Pharmacology Function biology +3

Drug liking and wanting, not impulsive action or reflection is increased by 4-fluoroamphetamine

Psychopharmacology May 31, 2018 Kim P. C. Kuypers, E. B. de Sousa Fernandes Perna, Patrick C. Dolder et al. 14 citations

BACKGROUND: New psychoactive substances (NPS) are chemical analogues designed to mimic the effects of various classic recreational drugs of abuse including MDMA, LSD, and cannabis. NPS use is associated with concern about the acute and longer-term effects particular substances might have, with abuse and addiction as potential consequences. Impulsivity and sensitivity to the rewarding effects of...

DOI: 10.1007/s00213-018-4931-7 (opens in new tab) Full text (opens in new tab) Addiction Action physics Clinical psychology Cognitive psychology

Depressive mood ratings are reduced by MDMA in female polydrug ecstasy users homozygous for the l-allele of the serotonin transporter

Scientific Reports January 12, 2018 Kim P. C. Kuypers, Rafael de la Torre, Magı́ Farré et al. 12 citations

Abstract MDMA exerts its main effects via the serotonergic system and the serotonin transporter. The gene coding for this transporter determines the expression rate of the transporter. Previously it was shown that healthy individuals with the short allelic variant (‘ s -group’) of the 5-HTTLPR-polymorphism displayed more anxiety and negative mood, and had a lower transcriptional efficiency...

Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH‐018: a phase 1, placebo‐controlled, pilot study

British Journal of Pharmacology November 22, 2017 Eef L. Theunissen, Nadia R. P. W. Hutten, Natasha L. Mason et al. 38 citations

BACKGROUND AND PURPOSE: Synthetic cannabinoids (often sold as Spice or K2) have become a very popular alternative to cannabis due to their easy access and portrayed safety. Controlled studies on the behavioural effects of synthetic cannabinoids are currently lacking, which hampers risk assessments of these compounds. EXPERIMENTAL APPROACH: This is a first attempt to assess the influence of a...

DOI: 10.1111/bph.14066 (opens in new tab) Cannabis Synthetic cannabinoids Placebo Dosing +4

Peripheral endocannabinoid concentrations are not associated with verbal memory impairment during MDMA intoxication

Psychopharmacology November 16, 2017 Eline Haijen, Magı́ Farré, Rafael de la Torre et al. 9 citations

Preclinical data have suggested involvement of the endocannabinoid (eCB) system in MDMA-induced memory impairment. Clinical research has shown that blockade of the 5-HT 2 receptor nulls memory impairment during MDMA intoxication. Interestingly, studies have demonstrated that the eCB and the 5-HT system interact. It was hypothesized that MDMA would cause an increase in eCB concentrations...

MDMA-induced indifference to negative sounds is mediated by the 5-HT2A receptor

Psychopharmacology July 22, 2017 Kim P. C. Kuypers, Rafael de la Torre, Magı́ Farré et al. 24 citations

MDMA has been shown to induce feelings of sociability, a positive emotional bias and enhanced empathy. While previous research has used only visual emotional stimuli, communication entails more than that single dimension and it is known that auditory information is also crucial in this process. In addition, it is, however, unclear what the neurobiological mechanism underlying these MDMA effects...

MDMA-Induced Dissociative State not Mediated by the 5-HT2A Receptor

Frontiers in Pharmacology July 11, 2017 Drew J. Puxty, Johannes G. Ramaekers, Rafael de la Torre et al. 33 citations

Previous research has shown that a single dose of MDMA induce a dissociative state, by elevating feelings of depersonalization and derealization. Typically, it is assumed that action on the 5-HT2A receptor is the mechanism underlying these psychedelic experiences. In addition, other studies have shown associations between dissociative states and biological parameters (heart rate, cortisol),...

DOI: 10.3389/fphar.2017.00455 (opens in new tab) MDMA Dissociative Pharmacology Hallucinogen +1

Multifaceted empathy of healthy volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies

Journal of Psychopharmacology April 3, 2017 Kim P. C. Kuypers, Patrick C. Dolder, Johannes G. Ramaekers et al. 88 citations

Previous placebo-controlled experimental studies have shown that a single dose of MDMA can increase emotional empathy in the multifaceted empathy test (MET) without affecting cognitive empathy. Although sufficiently powered to detect main effects of MDMA, these studies were generally underpowered to also validly assess contributions of additional parameters, such as sex, drug use history, trait...

Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking

Psychopharmacology July 19, 2016 Kim P. C. Kuypers, Jordi Riba, Mario de la Fuente Revenga et al. 204 citations

INTRODUCTION: Ayahuasca is a South American psychotropic plant tea traditionally used in Amazonian shamanism. The tea contains the psychedelic 5-HT2A receptor agonist N,N-dimethyltryptamine (DMT), plus β-carboline alkaloids with monoamine oxidase-inhibiting properties. Increasing evidence from anecdotal reports and open-label studies indicates that ayahuasca may have therapeutic effects in...

Cannabis and tolerance: acute drug impairment as a function of cannabis use history

Scientific Reports May 26, 2016 Johannes G. Ramaekers, J. H. van Wel, Desirée Spronk et al. 81 citations

Cannabis use history as predictor of neurocognitive response to cannabis intoxication remains subject to scientific and policy debates. The present study assessed the influence of cannabis on neurocognition in cannabis users whose cannabis use history ranged from infrequent to daily use. Drug users (N = 122) received acute doses of cannabis (300 μg/kg THC), cocaine HCl (300 mg) and placebo....